Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viva Biotech Holdings ( (HK:1873) ) has issued an update.
Viva Biotech Holdings reported 2025 revenue of RMB 1.73 billion, down 12.9% from a year earlier, but improved profitability, with gross profit slipping only 4.6% to RMB 655.6 million and gross margin rising to 37.9% from 34.6%. Net profit increased to RMB 269.3 million and adjusted non-IFRS net profit climbed to RMB 335.3 million, supported by higher earnings per share and management adjustments that strip out amortization, impairments, share incentive effects, and other non-recurring items to highlight underlying operating performance.
The company’s use of adjusted non-IFRS metrics underscores a focus on demonstrating core business resilience despite softer top-line growth, which may reassure investors about operational efficiency and profitability quality. By isolating non-cash and one-off charges, Viva Biotech aims to present a clearer view of its ongoing earnings power, potentially strengthening its position with stakeholders amid a challenging revenue environment.
The most recent analyst rating on (HK:1873) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Viva Biotech Holdings stock, see the HK:1873 Stock Forecast page.
More about Viva Biotech Holdings
Viva Biotech Holdings is a Hong Kong-listed biotechnology services group that provides drug discovery and development solutions. The company focuses on offering contract research and related services to pharmaceutical and biotech clients, generating revenue primarily through laboratory-based R&D and associated technology platforms.
Average Trading Volume: 10,085,575
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.42B
See more insights into 1873 stock on TipRanks’ Stock Analysis page.